AngioDynamics, Inc. - Common Stock (ANGO)

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

AngioDynamics raised its fiscal 2025 sales outlook to $285M-$288M and boosted its adjusted EBITDA forecast, expecting stronger Med Tech revenue growth.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

The medical technology company now expects net sales to be $285 to $288 million for the fiscal year 2025, up from previously issued guidance of $282 to $288 million, owing to increased medical technology net sales.

Should investors add these stocks on their watchlist? Insider buys suggest so.

Investors didn't like the medical technology company's fiscal 2025 Q1 update.

Sentiment continues to be cautious as traders play the “wait-and-watch” game until they see off Friday’s non-farm payroll data. The index futures traded moderately lower early Thursday.